Install
Clinical Trials (Phases I–IV)
Design, endpoints, enrollment, interim reads, and post‑market surveillance.
- 4 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
Latest in Clinical Trials (Phases I–IV)
ARWR: Interim ARO-MAPT Data Shows Potential for TRiM™ Platform in CNS Diseases
17+ hour, 19+ min ago (572+ words) //s27.q4cdn.com/906368049/files/pictures/2026/10152026_ARWR_1.png ARWR: Interim ARO-MAPT Data Shows Potential for TRiMâÃÂâ Platform in CNS Diseases Interim Data for ARO-MAPT Shows Promise for TRiMâÃÂâ Platform in CNS Diseases On October…...
FDA clears Roche's Enspryng for thyroid eye disease
1+ hour, 39+ min ago (565+ words) Roche has claimed US approval for IL-6 receptor antagonist Enspryng in a second indication – thyroid eye disease (TED) – that furthers its ambition to grow the drug into a blockbuster product. Enspryng (satralizumab) has been approved for the rare eye disorder neuromyelitis…...
Show Me The Money: Vaxcyte Delivers 100%+ Gains As Pneumococcal Vaccine Program Advances
3+ hour, 25+ min ago (199+ words) 2026 has been a breakout year for Vaxcyte Inc. (PCVX), with a string of positive pipeline developments lending its shares fresh momentum. The clinical-stage vaccine innovator aims to prevent bacterial infections, with its pipeline targeting diseases such as invasive pneumococcal disease,…...
FDA Priority Review Puts Satralizumab on Track as First MOGAD Drug
4+ hour, 5+ min ago (220+ words) The FDA granted priority review to satralizumab for MOGAD, positioning it to become the first approved treatment for the rare autoimmune disease. The supplemental biologics license application is based on results from the phase 3 METEOROID study (NCT05271409), in which satralizumab met…...
Satralizumab Reduces MOGAD Relapse Risk in Phase 3 METEOROID Trial
4+ hour, 6+ min ago (325+ words) NeurologyLive Satralizumab (Enspryng; Genentech) significantly reduced the risk of relapse compared with placebo in patients with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), according to findings from the phase 3 METEOROID trial (NCT05271409) Treatment with the agent, which has previously been approved…...
EC-104 outperforms Ozurdex in phase 2 BETTIS-1 trial for anti-VEGF–resistant DME
4+ hour, 19+ min ago (241+ words) Eclipse Life Sciences reports that its biodegradable 6-month fluocinolone acetonide implant met its primary safety end point and beat the dexamethasone implant on visual and anatomic measures at 24 weeks. Eligibility was deliberately narrow. Patients needed a documented suboptimal response to…...
HLB's Fate Hinges on November Phase 3 Results for Ophthalmic Drug — Will It Follow in Lyrfigtu's Footsteps?
11+ hour, 31+ min ago (661+ words) South Korea's HLB Group is approaching a critical milestone as its ophthalmic drug candidate prepares for U.S. Phase 3 results in November. Just about a month after securing FDA approval for Lyrfigtu (ingredient name: lirafugratinib), a cholangiocarcinoma treatment, the group's next growth…...
Licensed Ebola Vaccine Ervebo Triggered T Cells Against Bundibugyo in 13 of 20 Recipients, but Protection Remains Unproven
14+ hour, 12+ min ago (566+ words) single dose of Ervebo, the only licensed Ebola vaccine, prompted immune T cells that recognized the Bundibugyo virus in 13 of 20 vaccinated adults, according to research announced on October 14 by the German Center for Infection Research. Bundibugyo is the Ebola species…...
Round 1: After progression on a CDK4/6 inhibitor, should an actionable mutation determine treatment selection in PIK3CA wild-type disease?
9+ hour, 14+ min ago (1422+ words) HMP Global Learning Network Round 1: After progression on a CDK4/6 inhibitor, should an actionable mutation determine treatment selection in PIK3CA wild-type disease? The debate opens with a patient with PIK3CA wild-type disease progressing on an aromatase inhibitor plus a CDK4/6 inhibitor. The panelists debate…...
Antifibrotic Drug Pirfenidone Cuts Lung Injury Risk in Immunotherapy-Treated Lung Cancer Patients
9+ hour, 41+ min ago (66+ words) A phase II trial found that prophylactic pirfenidone significantly reduced grade 2 or higher radiation-induced lung injury in lung cancer patients previously treated with immune checkpoint inhibitors. Article Title: Prophylactic pirfenidone to prevent radiation- induced lung injury in ICI-pretreated lung cancer…...